StockData
Cellectis S.A. logo

Cellectis S.A. (CLLS) stock

CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$0.98−0.05 (-4.49%)

Close on Nov 19, 2026Market cap $98.71MP/E –Yield –

Cellectis free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2025 it was -$41.76M, down 304.7% from the year before. The highest annual figure on record is $20.41M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$41.76M-304.7%
FY2024Dec 31, 2024$20.41M–
FY2023Dec 31, 2023-$25.82M–
FY2022Dec 31, 2022-$89.88M–
FY2021Dec 31, 2021-$123.11M–
FY2020Dec 31, 2020-$124.34M–
FY2019Dec 31, 2019-$82.06M–
FY2018Dec 31, 2018-$72.85M–
FY2017Dec 31, 2017-$54.71M–
FY2016Dec 31, 2016-$46.41M–
FY2015Dec 31, 2015-$725.00K–

More Cellectis figures

See a number that looks wrong?